MARKET

MAZE

MAZE

Maze Therapeutics
NASDAQ
42.60
+1.11
+2.68%
After Hours: 43.44 +0.84 +1.97% 16:17 12/04 EST
OPEN
41.70
PREV CLOSE
41.49
HIGH
43.29
LOW
40.88
VOLUME
516.21K
TURNOVER
--
52 WEEK HIGH
43.29
52 WEEK LOW
6.71
MARKET CAP
2.05B
P/E (TTM)
-15.8748
1D
5D
1M
3M
1Y
5Y
1D
Maze Therapeutics Price Target Announced at $55.00/Share by Wells Fargo
Dow Jones · 16h ago
Wells Fargo Initiates Coverage On Maze Therapeutics with Overweight Rating, Announces Price Target of $55
Benzinga · 17h ago
MAZE THERAPEUTICS, INC. <MAZE.O>: WELLS FARGO INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $55
Reuters · 18h ago
MAZE Crosses Above Average Analyst Target
NASDAQ · 18h ago
Maze Therapeutics initiated with an Overweight at Wells Fargo
TipRanks · 20h ago
Maze Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 1d ago
Maze Therapeutics Price Target Raised to $60.00/Share From $50.00 by HC Wainwright & Co.
Dow Jones · 1d ago
HC Wainwright & Co. Maintains Buy on Maze Therapeutics, Raises Price Target to $60
Benzinga · 1d ago
More
About MAZE
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.

Webull offers Maze Therapeutics, Inc. stock information, including NASDAQ: MAZE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MAZE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MAZE stock methods without spending real money on the virtual paper trading platform.